株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

重症虚血肢:パイプライン製品の分析

Critical Limb Ischemia - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 219779
出版日 ページ情報 英文 126 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.46円で換算しております。
Back to Top
重症虚血肢:パイプライン製品の分析 Critical Limb Ischemia - Pipeline Review, H1 2017
出版日: 2017年05月16日 ページ情報: 英文 126 Pages
概要

重症虚血肢は、末梢動脈疾患(PAD)のなかで最も重篤な症状です。アテローム性動脈硬化症に関連した慢性的な炎症過程が原因となっています。主な症状には、足・つま先の痛みやしびれ、ただれ、皮膚感染症などがありますが、どれも発症後は治療不可能なものです。この疾患の治療目的は、冠動脈へのリスク要因の軽減(禁煙、コレステロール軽減など)や、疼痛の軽減、潰瘍の治癒、切断手術の回避、生活の質(QoL)の改善、生存率の向上などとなっています。

当レポートでは、世界各国での重症虚血肢(CLI)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

重症虚血肢 - 概要

重症虚血肢 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

重症虚血肢 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

重症虚血肢の治療薬開発に従事している企業

  • AnGes MG Inc
  • apceth Biopharma GmbH
  • Athersys Inc
  • BiogenCell Ltd
  • Caladrius Biosciences Inc
  • Cynata Therapeutics Ltd
  • Hemostemix Ltd
  • Histocell SL
  • ID Pharma Co Ltd
  • Integene International Holdings LLC
  • Juventas Therapeutics Inc
  • Kasiak Research Pvt Ltd
  • Kowa Company Ltd
  • Neurofx Inc
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • ReNeuron Group Plc
  • Symic Biomedical Inc
  • TikoMed AB
  • U.S. Stem Cell Inc
  • Vericel Corp
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd

薬剤プロファイル

重症虚血肢 - 休止中のプロジェクト

重症虚血肢 - 開発が中止された製品

重症虚血肢 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9300IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2017, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 12, 4 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Critical Limb Ischemia - Overview
    • Critical Limb Ischemia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Critical Limb Ischemia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Critical Limb Ischemia - Companies Involved in Therapeutics Development
    • AnGes MG Inc
    • apceth Biopharma GmbH
    • Athersys Inc
    • BiogenCell Ltd
    • Caladrius Biosciences Inc
    • Cynata Therapeutics Ltd
    • Hemostemix Ltd
    • Histocell SL
    • ID Pharma Co Ltd
    • Integene International Holdings LLC
    • Juventas Therapeutics Inc
    • Kasiak Research Pvt Ltd
    • Kowa Company Ltd
    • Neurofx Inc
    • Pharmicell Co Ltd
    • Pluristem Therapeutics Inc
    • ReNeuron Group Plc
    • Symic Biomedical Inc
    • TikoMed AB
    • U.S. Stem Cell Inc
    • Vericel Corp
    • VESSL Therapeutics Ltd
    • ViroMed Co Ltd
  • Critical Limb Ischemia - Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AdipoCell - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Alecmestencel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASCT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGC-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellgram-CLI - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLBS-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DVC-10101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HC-016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixmyelocel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JVS-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MultiGeneAngio - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NFx-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NK-104 NP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-05285401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-PAD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Refacell-CLI - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rejuveinix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ReN-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-030 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TM-700 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Critical Limb Ischemia - Dormant Projects
  • Critical Limb Ischemia - Discontinued Products
  • Critical Limb Ischemia - Product Development Milestones
    • Featured News & Press Releases
      • Jan 17, 2017: Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval
      • Jan 10, 2017: Pluristem's Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA
      • Nov 01, 2016: Pluristem's Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory Agency
      • Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada
      • Sep 08, 2016: Pluristem to Conduct Symposium on PLX-PAD Potential for the Treatment of Peripheral Artery Disease at a Multinational Conference on Vascular Medicine
      • Aug 09, 2016: Pluristem's Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe's Horizon 2020 Program
      • Aug 02, 2016: Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia
      • Jul 27, 2016: Pluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improve Recovery Following Surgery for Hip Fracture
      • Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia
      • Apr 18, 2016: Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los Angeles
      • Apr 18, 2016: Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb Ischemia
      • Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study
      • Dec 22, 2015: Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States
      • Dec 21, 2015: Pluristem Reaches Agreement with Japan's PMDA on Protocol for Final Trial Targeting Market Entry via Accelerated Pathway
      • Oct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Critical Limb Ischemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Critical Limb Ischemia - Pipeline by AnGes MG Inc, H1 2017
  • Critical Limb Ischemia - Pipeline by apceth Biopharma GmbH, H1 2017
  • Critical Limb Ischemia - Pipeline by Athersys Inc, H1 2017
  • Critical Limb Ischemia - Pipeline by BiogenCell Ltd, H1 2017
  • Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, H1 2017
  • Critical Limb Ischemia - Pipeline by Cynata Therapeutics Ltd, H1 2017
  • Critical Limb Ischemia - Pipeline by Hemostemix Ltd, H1 2017
  • Critical Limb Ischemia - Pipeline by Histocell SL, H1 2017
  • Critical Limb Ischemia - Pipeline by ID Pharma Co Ltd, H1 2017
  • Critical Limb Ischemia - Pipeline by Integene International Holdings LLC, H1 2017
  • Critical Limb Ischemia - Pipeline by Juventas Therapeutics Inc, H1 2017
  • Critical Limb Ischemia - Pipeline by Kasiak Research Pvt Ltd, H1 2017
  • Critical Limb Ischemia - Pipeline by Kowa Company Ltd, H1 2017
  • Critical Limb Ischemia - Pipeline by Neurofx Inc, H1 2017
  • Critical Limb Ischemia - Pipeline by Pharmicell Co Ltd, H1 2017
  • Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc, H1 2017
  • Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H1 2017
  • Critical Limb Ischemia - Pipeline by Symic Biomedical Inc, H1 2017
  • Critical Limb Ischemia - Pipeline by TikoMed AB, H1 2017
  • Critical Limb Ischemia - Pipeline by U.S. Stem Cell Inc, H1 2017
  • Critical Limb Ischemia - Pipeline by Vericel Corp, H1 2017
  • Critical Limb Ischemia - Pipeline by VESSL Therapeutics Ltd, H1 2017
  • Critical Limb Ischemia - Pipeline by ViroMed Co Ltd, H1 2017
  • Critical Limb Ischemia - Dormant Projects, H1 2017
  • Critical Limb Ischemia - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Critical Limb Ischemia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Critical Limb Ischemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top